196 related articles for article (PubMed ID: 29265175)
1. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
Weng HJ; Wang TS; Tsai TF
Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
[No Abstract] [Full Text] [Related]
2. Erythrodermic psoriasis and secukinumab: Our clinical experience.
Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
[No Abstract] [Full Text] [Related]
3. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
Dogra S; Bishnoi A; Narang T; Handa S
Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
[No Abstract] [Full Text] [Related]
4. Secukinumab for the treatment of residual psoriasis: a case series.
Malagoli P
J Dermatolog Treat; 2018; 29(sup1):12-13. PubMed ID: 30919723
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.
Cannavò SP; Postorino E; Aragona E; Bartolotta A; Papaianni V; Guarneri C
J Dermatolog Treat; 2018; 29(sup1):9-11. PubMed ID: 30247938
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
Lo Y; Tsai TF
Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
[No Abstract] [Full Text] [Related]
7. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
[TBL] [Abstract][Full Text] [Related]
8. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD; Castro LG; Romiti R
Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
[No Abstract] [Full Text] [Related]
9. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Heikkilä H; Ranki A; Cajanus S; Karvonen SL
Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
[No Abstract] [Full Text] [Related]
10. Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience.
Becatti M; Urban ML; Taurisano G; Mannucci A; Barygina V; Pescitelli L; Prignano F; Silvestri E; Taddei N; Lotti T; Fiorillo C; Emmi G
Dermatol Ther; 2018 Sep; 31(5):e12675. PubMed ID: 30133998
[No Abstract] [Full Text] [Related]
11. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
12. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.
Anzengruber F; Drach M; Maul JT; Kolios AG; Meier B; Navarini AA
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e274-e276. PubMed ID: 29356172
[No Abstract] [Full Text] [Related]
13. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Lewis TG; Tuchinda C; Lim HW; Wong HK
J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
[TBL] [Abstract][Full Text] [Related]
14. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
Lisby S; Gniadecki R
Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853
[No Abstract] [Full Text] [Related]
15. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
16. Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report.
Odorici G; Losi A; Ciardo S; Pellacani G; Conti A
Skin Res Technol; 2018 Feb; 24(1):160-162. PubMed ID: 29067742
[No Abstract] [Full Text] [Related]
17. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
Assefa GT; Kaneko S; Oguro H; Morita E
J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
[No Abstract] [Full Text] [Related]
18. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
[No Abstract] [Full Text] [Related]
19. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
Peccerillo F; Odorici G; Pellacani G; Conti A
Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
[No Abstract] [Full Text] [Related]
20. Secukinumab in multi-failure psoriatic patients: the last hope?
Magnano M; Loi C; Patrizi A; Sgubbi P; Balestri R; Rech G; Tasin L; Girardelli CR; Conti A; Odorici G; Campanati A; Offidani AM; Bardazzi F
J Dermatolog Treat; 2018 Sep; 29(6):583-585. PubMed ID: 29334270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
